Fremont, CA, United States of America

Pei Wang

USPTO Granted Patents = 5 

Average Co-Inventor Count = 5.6

ph-index = 1

Forward Citations = 8(Granted Patents)


Location History:

  • Fremont, CA (US) (2011)
  • Emeryville, CA (US) (2021)
  • Union City, CA (US) (2023)

Company Filing History:


Years Active: 2011-2023

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Pei Wang: Innovator in Antibody Therapeutics

Introduction

Pei Wang is a prominent inventor based in Fremont, CA, known for his significant contributions to the field of antibody therapeutics. With a total of five patents to his name, Wang has focused on developing innovative solutions for cancer treatment through his research and inventions.

Latest Patents

Wang's latest patents include the development of Anti-ROR2 antibodies, which are designed to exhibit specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR). These antibodies have potential applications in cancer treatment, extending to polynucleotide and polypeptide sequences that encode the antibodies, as well as therapeutic uses and diagnostic kits. Additionally, he has developed Anti-ROR1 antibodies, which share similar characteristics and applications in cancer therapy, including the creation of antibody-drug conjugates.

Career Highlights

Pei Wang is currently associated with Eureka Therapeutics, Inc., where he continues to advance his research in antibody development. His work has been instrumental in pushing the boundaries of therapeutic options available for cancer patients.

Collaborations

Wang collaborates with notable colleagues, including Cheng Liu and Su Yan, who contribute to the innovative environment at Eureka Therapeutics, Inc.

Conclusion

Pei Wang's contributions to the field of antibody therapeutics highlight his commitment to advancing cancer treatment through innovative inventions. His work continues to pave the way for new therapeutic options that can significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…